Protect Muscle on Ozempic

Older adults taking Ozempic or Wegovy are being told to protect muscle, not just lose weight, because rapid weight loss can also strip away strength. (aol.com) Ozempic and Wegovy contain semaglutide, a glucagon-like peptide-1 drug that is prescribed with a reduced-calorie diet and increased physical activity for chronic weight management and other conditions. A 2025 prescribing update for Wegovy says the drug is used alongside diet and exercise, not as a stand-alone treatment. (accessdata.fda.gov) The concern is not that semaglutide uniquely “eats” muscle, but that fast weight loss often reduces both fat and lean tissue. Cleveland Clinic obesity specialist Dr. W. Scott Butsch said muscle loss during GLP-1 treatment is tied to the weight-loss process itself, and he recommended strength training, enough protein and a slower pace. (health.clevelandclinic.org) A joint 2025 advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society said glucagon-like peptide-1 drugs can cut body weight by 5% to 18% in trials, but they also raise concerns about muscle and bone loss. The group called for baseline checks of muscle strength, function and body composition before and during treatment. (pmc.ncbi.nlm.nih.gov) That warning carries extra weight in older adults because aging already raises the risk of sarcopenia, the gradual loss of muscle mass and strength. The American Society on Aging said older patients on glucagon-like peptide-1 drugs need close attention to protein, vitamins, minerals, fiber and fluids as appetite and calorie intake fall. (generations.asaging.org) The same aging-focused review said studies of people on glucagon-like peptide-1 drugs found calorie intake fell by 16% to 39% versus placebo, and modeled 30% calorie cuts pushed 25% to 40% of people below estimated protein, vitamin B6 and zinc needs. It also said only 8% of patients saw a registered dietitian nutritionist within 180 days of starting one of these drugs, based on data presented at ObesityWeek. (generations.asaging.org) Body-composition research has added to the concern. A substudy from the STEP 1 semaglutide trial reported that adults who received semaglutide 2.4 milligrams lost both fat mass and lean mass over 68 weeks, even as the proportion of lean mass relative to total body weight increased after larger fat loss. (academic.oup.com) Doctors interviewed by AOL said the practical playbook for adults over 60 is straightforward: lift weights or use resistance bands, eat more protein, and ask clinicians to track strength and body composition instead of watching the scale alone. (aol.com) Researchers are now testing that approach directly. A registered clinical trial is evaluating whether resistance exercise and higher protein intake can preserve lean mass and physical function in people starting semaglutide or tirzepatide. (clinicaltrials.gov) For older patients, the message from geriatricians and obesity specialists is narrower than the hype around these drugs: losing 20 pounds is one outcome, but keeping the muscle needed to climb stairs, carry groceries and avoid falls is part of the treatment. (aol.com)